When Merck and Schering-Plough revealed Monday that the active ingredient in their top-selling cholesterol meds Zetia and Vytorin had flunked a clinical trial measuring its effect on artery plaque, they opened themselves up to a barrage of attacks.

Link to Article

Forbes.com